You can buy or sell BTAI and other stocks, options, ETFs, and crypto commission-free!
BioXcel Therapeutics, Inc. Common Stock, also called BioXcel Therapeutics, is a clinical stage biopharmaceutical company focuses on drug development. Read More The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
New Haven, Connecticut
52 Week High
52 Week Low
Seeking AlphaMay 12
BioXcel Therapeutics, Inc. CEO Vimal Mehta on Q1 2019 Results - Earnings Call Transcript
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2019 Earnings Conference Call May 7, 2019 8:30 AM ET Company Participants Brian Johnston - AVP-IR, The Ruth Group Vimal Mehta - Founder, CEO, President, Secretary & Director Richard Steinhart - CFO Vincent O'Neill - SVP & Chief Medical Officer Frank Yocca - Chief Scientific Officer Conference Call Participants Raghuram Selvaraju - H.C. Wainwright & Company Sumant Kulkarni - Canaccord Genuity Operator Good day, everyone, and welcome to the BioXcel Therap...
BioXcel Therapeutics to Present at the 2019 UBS Global Healthcare Conference
NEW HAVEN, Conn., May 09, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BTI") (Nasdaq:BTAI) today announced, that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the 2019 UBS Global Healthcare Conference, being held May 20-22, 2019 in New York, NY. BTI is a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology. Details of the presentatio...
Expected Aug 8, Pre-Market